Physician

John A. Peterson, MD

According to 2025 Medicare claims, John Peterson, MD (NPI: 1245211242) practices hematology/oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33707-4505.

Peterson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 702 traditional Medicare patients, billed 226,049 HCPCS/CPT codes, and received $3,049,181 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,305 prescription claims across 252 beneficiaries totaling $4,007,648 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 12 claims. Open Payments data shows 139 records totaling $3,328. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,750,554 to $4,007,648. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $4,836 to $1,902.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,019	344,670	$3,208,976
2016	1,059	334,669	$3,379,434
2017	1,082	353,555	$4,507,759
2018	1,079	347,800	$4,889,430
2019	1,068	347,970	$4,828,550
2020	887	327,095	$4,186,257
2021	807	278,653	$3,918,910
2022	844	296,527	$3,676,222
2023	813	259,244	$3,260,220
2024	702	226,049	$3,049,181

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	289	1,476	$1,750,554
2016	275	1,728	$2,414,521
2017	277	1,566	$2,614,186
2018	266	1,362	$2,815,895
2019	267	1,321	$2,187,748
2020	252	1,363	$2,686,322
2021	261	1,300	$3,162,259
2022	270	1,362	$3,584,051
2023	254	1,236	$3,863,417
2024	252	1,305	$4,007,648

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	183	$43,358
2016	N/R	196	$25,489
2017	N/R	128	$41,474
2018	11	133	$51,032
2019	33	121	$13,897
2020	13	88	$6,733
2021	N/R	40	$3,694
2022	N/R	N/R	N/R
2023	N/R	12	$270
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	324	634	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	290	450	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	185	299	$13
36415	Insertion of needle into vein for collection of blood sample	492	1,509	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	479	1,689	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	56	1,568	$995,719
Ibrance	Palbociclib	31	861	$404,173
Pomalyst	Pomalidomide	16	448	$348,281
Brukinsa	Zanubrutinib	18	540	$257,966
Jakafi	Ruxolitinib Phosphate	14	420	$235,785

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	139	$3,328	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John A. Peterson, MD?

Tedicare shows public-source Medicare data for John A. Peterson, MD (NPI 1245211242), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John A. Peterson, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John A. Peterson, MD?

John A. Peterson, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does John A. Peterson, MD have Open Payments data?

John A. Peterson, MD has 139 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.